(via NewsDirect)
Penny stock trading can offer investors an exciting opportunity to potentially reap significant gains. While a lot of investors might concentrate on more well-known stocks listed on significant exchanges, there are a ton of low-priced stocks that are currently trading that may offer promising investment potential.
In this article, we'll be delving into the world of penny stock trading and examining four stocks that are currently trading at attractive prices. These stocks could have the potential to experience explosive growth, and we'll be taking a closer look at what these companies offer.
While investing in penny stocks can come with increased risk, it also presents the opportunity for big rewards. As investors, it's important to carefully analyze the potential of each stock and assess their long-term prospects.
Penny stocks offer an exciting opportunity to invest in promising companies at a low price. Let's explore what these four stocks have to offer and why they may be worth considering for your portfolio.
This now allows EPAZ to seek international patents using established
EPAZ believes that the Smart Charging Pad is a major game changer in the drone charging arena. While most competitors are pricing their charging pads for drones weighing less than 55 pounds anywhere from
The ZenaDrone Smart Charging Pad allows the ZenaDrone 1000 to land on the charger for automatic charging. This allows the drone to be used in remote areas and operate in a true autonomous fashion. According to the company, the Smart Charging Pad has built-in computer vision to help it understand the environment around it and select the best option for receiving energy. It also has options for solar panels or wind power.
The ZenaDrone 1000, with its updated artificial intelligence (AI) predictive automation software, is a serious aircraft created for use by the military as well as in the oil and gas and agriculture industries. The ZenaDrone is meant to be a workhorse and to push the limits of future technology available today. The company's affordable offerings are getting noticed quickly.
Just a few weeks ago, back in February, EPAZ submitted Phase 1 SBIR proposals to the
Additional phases of the SBIR would give the business the opportunity to secure significant government contracts worth up to
With the US Military drone segment set to expand, and the potential for big revenue over the next few years, EPAZ should be on the list of any investor looking for a promising penny stock
On Tuesday, HNRC announced record results for the quarter ending in
While the stock finished Tuesday up nearly 75%, ultimately it could not carry the momentum into Wednesday, and the stock fell 22.66%.
Keep it on your shortlist for potential breakouts.
Kiromic BioPharma Inc. (NASDAQ: KRBP) is a clinical-stage biotherapeutics company using its proprietary DIAMOND artificial intelligence 2.0 target discovery engine to detect, develop, and commercialize cell therapies with a therapeutic focus on immuno-oncology
Last week, the company celebrated a victory when they released promising news regarding a preclinical trial. According to KRBP, the company received favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 (trademark: Deltacel) administered alone and in combination with a non-biological anti-tumor therapy in mice.
“These findings are in line with what we observed in a study evaluating Deltacel monotherapy at a dose more than 7 times higher than the maximum dose planned for the Deltacel clinical trial, and they confirm that Deltacel was well tolerated in mice, even when given as part of a combination therapy that further boosted its potency,” said
Kiromic plans to submit the Deltacel IND application to the FDA in the current first quarter. If accepted, plans call for the activation of the clinical trial process to begin in the second quarter of 2023. The planned clinical study will evaluate Deltacel in combination with a non-biological anti-tumor therapy for the treatment of non-small cell lung cancer.'
The stock finished up 12.59% on Wednesday.
A big winner from Wednesday's after hours trading session is Neoleukin Therapeutics Inc. (NASDAQ: NLTX). This biopharmaceutical company uses "de novo" protein design technology to develop next-generation immunotherapies for cancer, inflammation, and autoimmunity.
NLTX announced earlier this week that it had hired
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security.
Contact Details
+1 585-301-7700
markrmckelvie@gmail.com
Company Website
http://razorpitch.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source